Advertisement

Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort

      Abstract

      Background: The haptoglobin (Hp) locus is polymorphic with two major alleles denoted 1 and 2. Several recent prospective longitudinal studies have demonstrated conflicting results regarding whether there is an increase or decrease in the relative risk of coronary heart disease (CHD) conferred on individuals homozygous for the haptoglobin 1 allele (Hp 1-1). Methods: We sought to examine the relationship between Hp type and prevalent coronary heart disease in a cross-sectional study from a large community-based cohort, the Framingham Heart Offspring Study (n=3273). Results: Overall we found no relation between Hp type and CHD prevalence. In secondary analyses we found a different pattern of Hp type and CHD prevalence by diabetes status. In nondiabetics, compared with Hp 1-1, Hp 2-1 (OR 1.71, 95% CI 1.03, 2.83) was associated with excess prevalence of CHD. In contrast in diabetic individuals we observed the opposite pattern; Hp 2-1 (OR 0.49, 95% CI 0.24, 0.99) and Hp 2-2 (OR 0.46, 95% CI 0.22, 0.96) were associated with diminished prevalence of CHD. Conclusions: These data are consistent with an interaction between Hp type and diabetes in the prevalence of CHD. These findings will need to be confirmed in other cohorts and in longitudinal studies.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Steinberg D.
        • Witztum J.L.
        Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?.
        Circulation. 2002; 105: 2107-2111
        • Bowman B.H.
        • Kurosky A.
        Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation.
        Adv. Hum. Gen. 1982; 12: 189-261
        • Langlois M.R.
        • Delanghe J.R.
        Biological and clinical significance of haptoglobin polymorphism in humans.
        Clin. Chem. 1996; 42: 1589-1600
        • Melamed-Frank M.
        • Lache O.
        • Enav B.I.
        • Szafranek T.
        • Levy N.S.
        • Ricklis R.M.
        • et al.
        Structure/function analysis of the anti-oxidant properties of haptoglobin.
        Blood. 2001; 98: 3693-3698
        • Langlois M.R.
        • Delanghe J.R.
        • De Buyzere M.L.
        • Bernard D.R.
        • Ouyang J.
        Effect of haptoglobin on the metabolism of vitamin C.
        Am. J. Clin. Nutr. 1997; 66: 606-610
        • De Bacquer D.
        • De Backer G.
        • Langlois M.
        • Delanghe J.
        • Kasteloot H.
        • Kornitzer M.
        Haptoglobin polymorphism as a risk factor for coronary heart disease mortality.
        Atherosclerosis. 2001; 157: 161-166
        • Levy A.P.
        • Hochberg I.
        • Jablonski K.
        • Resnick H.E.
        • Lee E.T.
        • Best L.
        Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study.
        J. Am. Coll. Card. 2002; 40: 1984-1990
        • Kannel W.B.
        • Feinleib M.
        • McNamara P.M.
        • Garrison R.J.
        • Castelli W.P.
        An investigation of coronary heart disease in families: the Framingham Offspring Study.
        Am. J. Epidemiol. 1979; 110: 281-290
      1. Abbott RD, McGee DL. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 37: The probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. Bethesda, MD: National Heart, Lung and Blood Institute; 1987.

        • Hochberg I.
        • Roguin A.
        • Nikolsky E.
        • Chanderashekhar P.V.
        • Cohen S.
        • Levy A.P.
        Haptoglobin phenotype and coronary artery collaterals in diabetic patients.
        Atherosclerosis. 2002; 161: 441-446
        • Koch W.
        • Latz W.
        • Eichinger M.
        • Roguin A.
        • Levy A.P.
        • Schomig A.
        Genotyping of common haptoglobin Hp1/2 polymorphism based on PCR.
        Clin. Chem. 2002; 48: 1377-1382
      2. SAS/STAT User’s Guide, Version 8. Cary, NC: SAS Institute Inc.; 1999. p. 1903–2042.

      3. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, Wiley; 1989. p. 302.

      4. Suleiman M, Kapeliovich MR, Roguin A, Aronson D, Meisel SR, Shochat M, et al. Haptoglobin phenotype and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. Diab Care 2003;26:2699–700.

        • Langlois M.R.
        • Martin M.E.
        • Boelaert J.R.
        • Beaumont C.
        • Taes Y.E.
        • De Buyzere M.L.
        • et al.
        The haptoglobin 2-2 phenotype affects serum markers of iron status in health males.
        Clin. Chem. 2000; 46: 1619-1625
        • Yuan X.M.
        • Brunk U.T.
        • Olsson A.G.
        Effects of iron and hemoglobin loaded monocyte derived macrophages on oxidation and uptake of LDL.
        Arter. Thromb. Vasc. Biol. 1995; 15: 1345-1351
        • Shah S.V.
        • Alam M.G.
        Role of iron in atherosclerosis.
        Am. J. Kid Dis. 2003; 41: 80-83
        • Delanghe J.R.
        • Langlois M.R.
        Haptoglobin polymorphism and body iron stores.
        Clin. Chem. Lab. Med. 2002; 40: 212-216
        • Kristiansen M.
        • Graversen J.H.
        • Jacobsen C.
        • Sonne O.
        • Hoffman H.J.
        • Law S.K.
        • et al.
        Identification of the hemoglobin scavenger receptor.
        Nature. 2001; 409: 198-201
        • Asleh R.
        • Marsh S.
        • Shilkrut M.
        • Binah O.
        • Guetta J.
        • Lejbowicz F.
        • et al.
        Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease.
        Circ. Res. 2003; 92: 1193-1200
        • Bernard D.
        • Christophe A.
        • Delanghe J.
        • Langlois M.
        • De Buyzere M.
        • Comhaire F.
        The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism.
        Redox Rep. 2003; 8: 41-46
      5. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients, N Eng J Med 432(2000)154–160.

      6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high risk individuals: a randomised placebo controlled trial. Lancet 3609(2002)23–33.